查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995341

神经痛治疗市场：2026年至2032年全球市场预测（依治疗方法、给药途径、药物类别、最终用户、通路和适应症划分）

Neuralgia Treatment Market by Treatment Type, Delivery Mode, Drug Class, End User, Distribution Channel, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经痛治疗市场价值将达到 13.5 亿美元，到 2026 年将成长到 15.3 亿美元，到 2032 年将达到 32.4 亿美元，复合年增长率为 13.24%。

主要市场统计数据
基准年 2025 13.5亿美元
预计年份：2026年 15.3亿美元
预测年份 2032 32.4亿美元
复合年增长率 (%) 13.24%

对当前神经痛治疗领域中涉及的临床、技术和治疗方案等多方面因素进行了权威概述。

神经痛的临床治疗面临许多挑战，涉及慢性疼痛管理、不断发展的医疗设备创新以及多样化的药物治疗策略。近年来，临床路径不断扩展，体现出一种更全面的治疗方法，除了传统的药物治疗外，还涵盖了非药物疗法。临床医师越来越重视疗效、耐受性和长期功能预后的平衡，这促使治疗流程的发展和应用方式改变。本文透过检验临床证据、病患偏好和医疗保健系统压力之间的相互作用，概述了当前的治疗格局，重点在于重塑临床实践模式和商业性利益的关键因素。

深入了解技术、临床和医疗保健系统因素的融合，这些因素正在重新定义神经痛治疗的治疗路径和商业性方法。

在技​​术创新、护理模式转变以及临床实践中对疗效日益增长的期望的推动下，神经痛的治疗现状正经历着变革性的转变。神经调控疗法硬体和软体的进步拓展了药物治疗以外的治疗选择，使临床医生能够根据患者的表型和疼痛病因制定个人化的干预措施。同时，诊断准确性的提高和生物标记研究的进展有助于治疗分层，从而实现早期疗育和更精确的治疗反应追踪。除了这些技术变革之外，人们越来越重视多方面的治疗方法，将介入治疗、復健和行为疗法结合，以实现持续的症状控制和功能恢復。

从分析的观点探讨了近期关税措施如何重组了与神经痛治疗相关的供应链的韧性、筹资策略和商业规划。

美国2025年实施的新关税措施正在对神经痛治疗相关医疗产品的采购、筹资策略和供应链设计产生影响。进口关税和贸易调整迫使相关人员重新评估其供应商组合，优先考虑成本控制，并探索替代筹资策略，以维持专用医疗设备、药品原料和辅助用品的持续供应。采购团队正在加强对总到岸成本和韧性指标的评估，因此，一些製造商和经销商正在分散其製造地，并与战略合作伙伴重新谈判合约条款，以在确保关键治疗药物供应的同时，缓解利润率压力。

从治疗方法、给药方法、最终用户、分销、适应症和药物分类等方面进行策略性细分，以确定差异化的机会领域和营运重点。

多维度细分观点揭示了不同治疗类型、给药途径、最终用户、分销管道、适应症和药物类别中清晰的机会领域和营运考虑。按治疗类型分析，区分了针灸、神经调控疗法和物理疗法等非药物疗法与药物疗法，每种疗法都有其独特的启动驱动因素、报销趋势和证据要求。按给药途径细分，区分了注射剂、口服剂、外用剂和经皮製剂，这一区分对于了解用药依从性模式、优先开发製剂以及整合用于缓释或靶向给药技术的医疗设备至关重要。依最终使用者细分，突显了门诊手术中心、居家医疗机构、医院和专科诊所等不同机构的营运需求和采购行为，每种环境都会影响服务设计、人员配置模式和资本投资决策。

全面的区域分析将揭示美洲、欧洲、中东和非洲以及亚太地区独特的报销、监管和医疗保健服务趋势如何影响策略和实施。

区域趋势对美洲、欧洲、中东和非洲（EMEA）以及亚太地区的临床实务模式、报销架构和供应链结构都有显着影响。在美洲，医疗服务的发展趋势凸显了门诊服务的扩展、打包支付模式的试验以及与私人保险公司的密切合作，这些因素共同塑造了介入疗法和数位疗法的普及曲线。该地区的临床医生和管理人员通常优先考虑扩充性的门诊解决方案和整合式护理路径，以减少住院次数，同时保持临床监管。美洲的监管流程和报销机制既为创新提供了机会，也为製造商带来了挑战，他们必须证明产品的相对价值。

评估产品创新、策略联盟和对真实世界数据的投资如何影响神经痛治疗领域的竞争定位和商业化。

神经痛治疗领域主要企业之间的竞争格局取决于器材平台、製剂科学、临床证据生成和伙伴关係模式的创新。老牌製药公司正利用其深厚的治疗专业知识和分销网络来保护其核心药物产品线，同时有选择地投资于新型製剂和局部/经皮给药系统，以解决耐受性和依从性方面的挑战。同时，医疗设备製造商正专注于具有可程式设计、封闭回路型或微创功能的下一代神经调节系统，并透过令人信服的临床数据和基于服务的交付模式来确立自身地位。

为了在神经痛治疗领域实现永续价值，高阶主管需要采取明确且优先的行动，以协调产品创新、供应弹性、证据产生和分销策略。

产业领导者应优先采取一系列切实可行的措施，使临床创新与永续的经营模式和稳健的营运相契合。首先，实现生产和供应商网络多元化，可降低受地缘政治因素和关税波动的影响，同时能够快速回应不断变化的需求。其次，进行神经调控疗法的研究，并投资于整合介入和復健的临床项目，能够使产品和服务脱颖而出，并满足难治性神经痛患者尚未满足的需求。第三，扩大居家和门诊服务体系，既能满足病患对便利性的需求，又能支持降低系统成本和提高用药依从性的照护模式。

对用于建构关于神经痛治疗方法的实用见解和稳健细分的初级、次级和真实世界证据方法进行综合概述。

本研究采用整体调查方法，整合了多个资料流，结合了质性研究、系统性二次分析和针对性的真实世界证据评估。一手数据包括对临床医生、采购经理、保险公司和医疗设备专家的结构化访谈，旨在了解医疗专业人员的观点和营运限制。二次分析涵盖了同行评审文献、监管指导文件、临床试验註册数据和公共声明，以阐明临床标准和报销趋势的背景。同时，也利用真实世界使用数据和理赔数据层面的分析来检验护理模式并从中获得细分洞察。在整个研究过程中，资料来源和调查方法始终保持透明。

简明扼要地总结道，协作创新、基于证据的价值证明和稳健的运作策略对于推进神经痛的治疗至关重要。

总之，神经痛治疗生态系统正朝着更整合、实证且以病人为中心的照护模式转变。神经调控疗法和标靶递送技术的进步，以及不断演变的医疗服务模式和支付方期望，为製造商和医疗服务提供者带来了机会和实施挑战。对于寻求持续影响力和商业性可行性的利害关係人相关人员，强调供应链韧性、严谨的实证实践和个人化分销策略的策略性应对至关重要。将临床创新与支付方可接受的价值提案和可扩展的护理模式相结合，将决定哪些治疗方法能够被广泛采用并为患者带来有意义的疗效。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的神经痛治疗市场

  • 非药物疗法
    • 针刺
    • 神经调控疗法
    • 物理治疗
  • 药物治疗

第九章：神经痛治疗市场：依给药方式划分

  • 注射药物
  • 口服
  • 外用
  • 经皮吸收

第十章 神经痛治疗市场：依药物类别划分

  • 抗惊厥药物
  • 抗忧郁症
  • 局部麻醉剂
  • NSAIDs
  • 阿片类药物
  • 外用製剂

第十一章：神经痛治疗市场：依最终用户划分

  • 门诊手术中心
  • 家庭医疗保健
  • 医院
  • 专科诊所

第十二章：神经痛治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：神经痛治疗市场：依适应症划分

  • 化疗引起的神经痛
  • 糖尿病神经病变
  • 带状疱疹后遗症神经痛
  • 三叉神经痛

第十四章：神经痛治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：神经痛治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 神经痛治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国神经痛治疗市场

第十八章：中国神经痛治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-F74E250AD635

The Neuralgia Treatment Market was valued at USD 1.35 billion in 2025 and is projected to grow to USD 1.53 billion in 2026, with a CAGR of 13.24%, reaching USD 3.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.35 billion
Estimated Year [2026] USD 1.53 billion
Forecast Year [2032] USD 3.24 billion
CAGR (%) 13.24%

An authoritative overview of the multifactorial clinical, technological, and delivery considerations that define the current neuralgia treatment environment

Neuralgia presents a complex clinical challenge that intertwines chronic pain management, evolving device innovation, and diverse pharmacological strategies. In recent years, clinical pathways have broadened to reflect a more integrated approach that encompasses non-pharmacological modalities alongside traditional drug therapies. Clinicians increasingly balance efficacy with tolerability and long-term functional outcomes, prompting a shift in how treatment algorithms are developed and adopted. This introduction frames the current therapeutic environment by examining the interplay between clinical evidence, patient preferences, and health system pressures, and by highlighting the critical drivers that are reshaping practice patterns and commercial priorities.

Moreover, patient-centered care models and technological progress are accelerating changes in care delivery. Telemedicine and decentralized care platforms are altering touchpoints for diagnosis, monitoring, and ongoing management. At the same time, regulatory evolution and reimbursement scrutiny require clearer value demonstration for both established and novel therapies. Consequently, stakeholders must navigate a dynamic landscape where scientific advances, supply chain considerations, and payer expectations jointly influence decision-making. This section establishes the baseline context for deeper analysis across transformational trends, segmentation nuances, regional variation, and strategic implications that follow.

Insights into the converging technological, clinical, and health system forces that are redefining therapeutic pathways and commercial approaches in neuralgia treatment

The neuralgia treatment landscape is undergoing transformative shifts driven by technological innovations, changing care models, and heightened expectations for real-world outcomes. Advances in neuromodulation hardware and software have expanded therapeutic options beyond pharmacology, enabling clinicians to tailor interventions to patient phenotype and pain etiology. Concurrently, improvements in diagnostic precision and biomarker research are informing treatment stratification, allowing earlier intervention and better tracking of therapeutic response. These technological inflections are complemented by an increased emphasis on multimodal regimens that integrate interventional, rehabilitative, and behavioral strategies to achieve durable symptom control and functional recovery.

At the system level, payers and providers are adopting value-based frameworks that prioritize long-term patient outcomes and cost-effectiveness, prompting manufacturers and service providers to generate evidence that extends beyond short-term symptom relief. Patient empowerment and digital health tools are shifting expectations regarding access, monitoring, and therapy personalization, which in turn pressures traditional distribution and engagement models. Finally, supply chain resilience and regional manufacturing strategies have gained prominence; stakeholders now weigh domestic and nearshore production, device lifecycle support, and component sourcing in their operational planning. Taken together, these converging trends are fostering a more responsive, evidence-driven, and patient-centered approach to neuralgia care.

An analytical perspective on how recent tariff measures have reshaped supply chain resilience, procurement strategies, and commercial planning relevant to neuralgia therapies

The introduction of new tariff measures in the United States in 2025 has reverberated across medical product sourcing, procurement strategies, and supply chain design relevant to neuralgia therapies. Import duties and trade adjustments have led stakeholders to reassess supplier portfolios, prioritize cost containment, and explore alternative sourcing strategies to maintain continuity of specialized devices, pharmaceutical ingredients, and adjunctive supplies. Procurement teams are increasingly evaluating total landed cost and resilience metrics, leading some manufacturers and distributors to diversify manufacturing footprints or to renegotiate terms with strategic partners to manage margin pressure while preserving access to critical therapies.

Beyond immediate procurement impacts, tariffs have influenced strategic planning for product launches, clinical trials, and service expansion. Health systems and ambulatory providers are assessing inventory management practices and contracting frameworks to buffer against price volatility. At the same time, some manufacturers have accelerated localization or nearshoring efforts for high-value components and finished devices to mitigate exposure to trade policy shifts. These adaptations are accompanied by intensified dialogue with payers to adjust reimbursement constructs and with regulatory authorities to expedite pathways for domestically produced devices and therapies. In sum, the tariff environment has triggered a recalibration of commercial and operational strategies across the neuralgia treatment ecosystem, emphasizing agility, cost transparency, and supply assurance.

A strategic synthesis of treatment, delivery, end-user, distribution, indication, and drug-class segmentation to reveal differentiated opportunity zones and operational priorities

A multidimensional segmentation lens reveals distinct opportunity zones and operational considerations across treatment types, delivery modes, end users, distribution channels, indications, and drug classes. When analyzed by treatment type, the space differentiates non-pharmacological approaches such as acupuncture, neuromodulation, and physical therapy from pharmacological interventions, each presenting unique adoption levers, reimbursement dynamics, and evidence requirements. Delivery mode segmentation separates injectable, oral, topical, and transdermal options, and this distinction matters for adherence patterns, formulation development priorities, and device integration for sustained-release or targeted delivery technologies. End user segmentation highlights the differing operational needs and procurement behaviors across ambulatory surgical centers, home healthcare providers, hospitals, and specialty clinics, with each setting influencing service design, staffing models, and capital investment decisions.

Distribution channel segmentation underscores the strategic role played by hospital pharmacies, online pharmacies, and retail pharmacies in ensuring patient access, patient education, and medication adherence support. Indication-focused segmentation-comprising chemotherapy-induced neuralgia, diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia-reveals heterogeneity in clinical pathways, comorbidity burdens, and stakeholder engagement needs that should inform targeted clinical development and market access strategies. Finally, drug class segmentation encompassing anticonvulsants, antidepressants, local anesthetics, NSAIDs, opioids, and topical agents clarifies therapeutic positioning, safety and monitoring considerations, and opportunities for combination approaches. Synthesizing these segmentation dimensions facilitates sharper product development priorities, tailored commercial strategies, and nuanced value propositions for distinct stakeholder groups.

A comprehensive regional analysis revealing how distinct reimbursement, regulatory, and care-delivery dynamics in the Americas, EMEA, and Asia-Pacific shape strategy and adoption

Regional dynamics exert a pronounced influence on clinical practice patterns, reimbursement frameworks, and supply chain configurations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, care delivery trends emphasize outpatient expansion, bundled payment experimentation, and robust private payer engagement, which together shape adoption curves for interventional and digital therapies. Clinicians and administrators in this region often prioritize scalable outpatient solutions and integrated care pathways that reduce hospital utilization while maintaining clinical oversight. Regulatory pathways and reimbursement mechanisms in the Americas present both opportunities for innovation and challenges for manufacturers that must demonstrate comparative value.

In Europe, Middle East & Africa, and Asia-Pacific, heterogeneity in healthcare infrastructure, regulatory regimes, and population burden of neuralgia-related conditions drives differentiated strategies. The Europe, Middle East & Africa region tends to emphasize centralized HTA assessment, cross-border innovation diffusion, and public payer negotiation, encouraging manufacturers to build robust clinical dossiers and real-world evidence to support reimbursement. Asia-Pacific markets often combine rapid adoption of digital care models with a strong focus on cost efficiency and domestic manufacturing capabilities, leading to competitive dynamics that favor scalable, low-cost interventions and local partnerships. Across all regions, supply chain localization, regulatory alignment, and culturally informed patient engagement strategies are critical to successful market entry and sustained uptake.

An evaluation of how product innovation, strategic alliances, and real-world evidence investments are shaping competitive positioning and commercialization in neuralgia care

Competitive dynamics among leading companies in the neuralgia treatment space are defined by innovation in device platforms, formulation science, clinical evidence generation, and partnership models. Established pharmaceutical manufacturers leverage deep therapeutic expertise and distribution networks to defend core drug-class franchises while selectively investing in novel formulations and topical or transdermal systems that address tolerability and adherence gaps. Concurrently, medtech firms are focusing on next-generation neuromodulation systems that offer programmable, closed-loop, or minimally invasive capabilities, positioning themselves through compelling clinical data and service-based delivery models.

Smaller specialized companies and startups are accelerating innovation in areas such as targeted delivery technologies, digital therapeutics, and adjunctive rehabilitation tools, often partnering with larger organizations for scale, regulatory navigation, and market access. Strategic alliances between device makers, pharmaceutical companies, and care providers are increasingly common, enabling integrated solutions that combine pharmacological and non-pharmacological elements. Across competitors, emphasis on robust real-world evidence, post-market surveillance, and iterative product improvement has become central to sustaining differentiation in an environment where payers demand demonstrable outcomes and long-term value.

Clear, prioritized actions for executives to align product innovation, supply resilience, evidence generation, and distribution strategies to capture durable value in neuralgia care

Industry leaders should prioritize a set of actionable measures that align clinical innovation with sustainable commercial models and resilient operations. First, diversifying manufacturing and supplier networks will reduce exposure to geopolitical and tariff-driven disruptions while enabling faster responsiveness to demand shifts. Second, investing in neuromodulation research and in clinical programs that integrate interventional and rehabilitative care can differentiate offerings and address unmet needs in refractory neuralgia. Third, expanding capabilities for home-based and ambulatory delivery will meet patient preferences for convenience and support care models that lower system costs and improve adherence.

Additionally, companies should strengthen evidence generation across both randomized and real-world studies to satisfy payer requirements and to support differentiated pricing and contracting strategies. Commercial teams must refine channel strategies to optimize partnerships with hospital pharmacies, online pharmacy platforms, and retail chains, ensuring coherent patient support programs and adherence solutions. Finally, fostering collaborations with specialty clinics, payers, and professional societies will accelerate guideline inclusion and the diffusion of best practices. Collectively, these recommendations promote durable competitive advantage by aligning clinical value with operational resilience and payer-validated outcomes.

A transparent overview of the integrated primary, secondary, and real-world evidence methods used to develop actionable insights and robust segmentation for neuralgia therapies

This research synthesized multiple data streams through an integrated methodology combining primary qualitative inquiry, systematic secondary analysis, and targeted real-world evidence assessment. Primary inputs included structured interviews with clinicians, procurement leaders, payers, and device specialists to capture practitioner perspectives and operational constraints. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public policy statements to contextualize clinical standards and reimbursement trends. In parallel, real-world utilization data and claims-level analyses were used to validate care patterns and to inform segmentation insights, always with attention to data provenance and methodological transparency.

Analytical approaches included cross-segmentation mapping, stakeholder impact assessment, and supply chain scenario planning to identify strategic inflection points and operational risk. Where possible, triangulation methods were applied to reconcile differences between trial evidence, guideline recommendations, and routine practice. Limitations of the methodology-such as regional data variability and evolving regulatory environments-were explicitly acknowledged, and sensitivity checks were performed to ensure that recommendations remained robust under alternative assumptions. Ethical standards and data governance protocols guided all primary engagements, ensuring confidentiality and compliance with applicable research norms.

A concise synthesis underscoring the imperative for coordinated innovation, evidence-based value demonstration, and resilient operational strategies to advance neuralgia care

In closing, the neuralgia treatment ecosystem is moving toward more integrated, evidence-driven, and patient-centric models of care. Technological advances in neuromodulation and targeted delivery, combined with evolving care delivery paradigms and payer expectations, are creating both opportunities and execution challenges for manufacturers and providers. Strategic responses that emphasize supply chain resilience, rigorous evidence generation, and tailored distribution strategies are essential for stakeholders seeking sustained impact and commercial viability. Aligning clinical innovation with payer-acceptable value propositions and scalable care models will determine which therapies achieve broad adoption and deliver meaningful patient outcomes.

Stakeholders that proactively adapt to regional nuances, prioritize partnerships across the care continuum, and commit to transparent outcome measurement will be best positioned to navigate regulatory complexity and competitive pressures. The path forward requires coordinated efforts across R&D, commercial, and operational functions to translate scientific advances into accessible and affordable care. Ultimately, success will be measured by the ability to relieve patient suffering, improve functional status, and integrate neuralgia management into holistic chronic pain strategies that are sustainable for health systems and acceptable to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuralgia Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological
    • 8.1.1. Acupuncture
    • 8.1.2. Neuromodulation
    • 8.1.3. Physical Therapy
  • 8.2. Pharmacological

9. Neuralgia Treatment Market, by Delivery Mode

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Neuralgia Treatment Market, by Drug Class

  • 10.1. Anticonvulsants
  • 10.2. Antidepressants
  • 10.3. Local Anesthetics
  • 10.4. NSAIDs
  • 10.5. Opioids
  • 10.6. Topical Agents

11. Neuralgia Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Neuralgia Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Neuralgia Treatment Market, by Indication

  • 13.1. Chemotherapy Induced Neuralgia
  • 13.2. Diabetic Neuropathy
  • 13.3. Postherpetic Neuralgia
  • 13.4. Trigeminal Neuralgia

14. Neuralgia Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Neuralgia Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Neuralgia Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Neuralgia Treatment Market

18. China Neuralgia Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Eli Lilly and Company
  • 19.7. GlaxoSmithKline plc
  • 19.8. Grunenthal GmbH
  • 19.9. Johnson & Johnson
  • 19.10. Novartis AG
  • 19.11. Pfizer Inc.
  • 19.12. Sanofi S.A.
  • 19.13. Teva Pharmaceutical Industries Ltd.
  • 19.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. G7 NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NATO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)